Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection for Radiotherapy Adverse Reactions in Lung Cancer
NCT02346318Phase 4Unknown
- Sponsor
- Beijing Zheng Ju Medical Technology Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection in lung cancer (2 arms), sponsored by Beijing Zheng Ju Medical Technology Co., Ltd. Primary endpoint: The rates of incidence and the degree of adverse reactions caused by radiotherapy at 6 months. Status: unknown.
02
Drugs
compound kushen injection
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT02346318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346318.